Sale of de-addiction drug restricted in state
The sale of buprenorphine sublingual medicine against opioid dependence has been restricted to the de-addiction centres in the state, and from now it will not be available at the chemist’s. The medicine is used to treat addiction to opioid drugs such as heroin and narcotic painkillers.punjab Updated: Dec 28, 2014 09:50 IST
The sale of buprenorphine sublingual medicine against opioid dependence has been restricted to the de-addiction centres in the state, and from now it will not be available at the chemist’s.
The medicine is used to treat addiction to opioid drugs such as heroin and narcotic painkillers. On November 28 also, state drug controller Ajay Singla had issued a circular in this regard to all assistant drug controllers, zonal licensing authorities, and drug inspectors in the state. In Punjab, the tablet will be available only at 75 de-addiction centres, of which 50 are private.
Sources said the reports of addicts’ misusing this prescription drug had made the department concerned stop retail. “The decision was taken as per the guidelines of the drugs controller general of India in New Delhi,” said Singla, adding: “Buprenorphine sublingual tablet (0.4mg and 2mg), either alone or in combination with Naloxone, is approved specifically for opioid de-addiction and is meant for approved de-addiction centres only. As these preparations are not meant for pain management and palliative care, they will not be available with retail chemists for OPD patients.”
Singla further said his office had informed the manufacturers concerned not to send any medicine to the retail sector. Recently, police had arrested Dr Sudha Vasudev, in charge of the de-addiction centre at Lord Mahavira Civil Hospital, Ludhiana; and Dr Ashish Sharma of Ivy hospital under the Narcotic Drugs and Psychotropic Substances Act from Machhiwara on the charge that they possessed 18,050 tablets of buprenorphine and had been selling the drug without license. Punjab and Chandigarh unit of the Indian Psychiatric Association (PUNCIPS) had opposed the action and called for boycotting the recommending of buprenorphine.
The Ludhiana psychiatric forum has opposed the move, saying it will make an adverse impact on people under treatment. “It will lead to a massive increase in the number of substance-dependent individuals and criminal cases, leading to fear, withdrawal effects, and relapse,” said Ludhiana psychiatrist Dr Rajeev Gupta.
PUNCIPS president Dr Satish Verma said the medicine was “very effective”, and restricting its sale would harm patients. On the question of mephedrone’s being alternative to buprenorphine, he said: “Buprenorphine can be administered to patients at home but since mephedrone is in liquid form, the patient has to take it in a doctor’s presence, which they find difficult to visit again and again.”